5th Dermatology Drug Development Summit Europe

Going Beyond Symptomatic Treatment: Uncovering Targetable Pathways, Translational Techniques and Navigating European Healthcare Infrastructure to Advance Novel R and D for Small Molecules, Biologics, mAb's and beyond!

The huge unmet need for more efficacious and durable therapies in inflammatory-mediated dermatological diseases reinforces the critical importance for the community to unite at the 5th Dermatology Drug Development Summit Europe, to collaboratively address the prevailing barriers facing pipeline progression and patient access in Europe.

With successful clinical readouts from pharma's targeting of a range of inflammatory mechanisms coming thick and fast, novel drug targets emerging and exciting advances in biomarker-driven drug development, the therapeutic promise for pipelines to achieve superior efficacy and safety for target patient populations is at an all-time high.

This is your only industry-led forum uniting large pharma, biotech, academic and clinician KOLs under the common goal to translate cutting edge R and D towards long term improvements in patient QoL whilst navigating complex European healthcare infrastructure for transforming clinical practice.

Join renowned leaders including Sanofi, Nektar Therapeutics and Moonlake Therapeutics to gain unrivalled insight into pipeline strategies translating Psoriasis and Atopic Dermatitis successes, to first-in-class treatments for itch, Prurigo Nodularis, Acne, Hidradenitis Suppurativa, Chronic Spontaneous Urticaria and more!

Your definitive platform pairing ground-breaking research with expert-led intelligence to evolve your dermatology portfolio, be equipped to deliver novel therapies with superior and long-lasting efficacy this April!

Prices:
Industry - Conference + 2 Workshops: EUR 3797.00,
Industry - Conference + 1 Workshop: EUR 3298.00,
Industry - Conference Only: EUR 2799.00,
Service Provider - Conference + 2 Workshops: EUR 4697.00,
Service Provider - Conference + 1 Workshop: EUR 4098.00,
Service Provider - Conference Only: EUR 3499.00

Speakers: Anna-Lena Spetz, CSO, TIRmed, Betsy Hughes- Formella, Co-Founder and Chief Scientific Officer, Dermaliq Therapeutics, David Cook, Chief Scientific Officer, Blueberry Therapeutics Ltd, Elena Rizova, Vice President, Head Medical Affairs, Biogen Intercontinental Region, Biogen, Elisabeth Riedl, Associate Professor - Department of Dermatology, Medical University of Vienna, Farzan Solimani, Physician, Charite, Universitatsmedizin Berlin, Guido Wurth, Global Head of Programs, Affibody AB, Jonathan Zalevsky, Chief Research and Development Officer, Nektar Therapeutics, Kim Kjoller, Chief Executive Officer, Union Therapeutics, Kristian Reich, Chief Scientific Officer, MoonLake Immunotherapeutics AG, Laurence Cheng, Vice President, RAPT Therapeutics, Mathias Schmelcher, Senior Scientific Advisor, MICREOS, Ofer Toledano, Vice President - Research and Development, Sol Gel Technologies, Pnina Fishman, Executive Chairman and CSO, Can-Fit, BioPharma Ltd, Robert Rissmann, Professor - Translational Dermatology, Leiden University, Simmi Wiggins, Regional Lead - Immunology and Medical, Sanofi, Tamar Ben Yedidia, CSO and clinical management, Scinai Immunotherapeutics, Thorsten Thormann, Stretegic Advisor, Independant Consultant, Todd Krueger, President and CEO, AOBiome

Others Details

Brochure: https://go.evvnt.com/2124113-3?pid=6581